Pipeline
Forest small banner

Glycostem’s pipeline has the potential to redefine standards of care across various type of cancer where there is an urgent medical need.

Therapy
Product
Indication
Cell
Development
Pre-clinical
Phase I
Phase II
Phase III
Partner

oNKord®

Inaleucel
AML
NK Cell
Phase I

medac (EU)

inno.N (Japan and Korea)

oNKord®
Inaleucel
AML
NK Cell
I
2025

medac (EU)

inno.N (Japan and Korea)

Inaleucel
Solid tumors (e.g. uCCLM)
NK Cell
Pre-clinical
oNKord®
Inaleucel
Solid tumors (e.g. uCCLM)
NK Cell
PRE
Inaleucel
Metastatic solid tumors
Combination Therapy: NK cell + mAb/ICE
Pre-clinical
oNKord®
Inaleucel
Metastatic solid tumors
Combination Therapy: NK cell + mAb/ICE
PRE
TBA

viveNK™

GTA103
OGD2+ Solid Tumors
CAR-NK
Pre-clinical
viveNK™
GTA103
OGD2+ Solid Tumors
CAR-NK
PRE
TBA
GTA103
N/A
CAR-NK
Development
viveNK™
GTA103
N/A
CAR-NK
DEV
TBA
GTA201
N/D
TCR-NK
Development
viveNK™
GTA201
N/D
TCR-NK
DEV
TBA
Therapy
Phase
Partner

oNKord®

Inaleucel
AML
NK Cell
Phase I

medac (EU)

inno.N (Japan and Korea)

oNKord®
Inaleucel
AML
NK Cell
I
2025

medac (EU)

inno.N (Japan and Korea)

Inaleucel
Solid tumors (e.g. uCCLM)
NK Cell
Pre-clinical
oNKord®
Inaleucel
Solid tumors (e.g. uCCLM)
NK Cell
PRE
Inaleucel
Metastatic solid tumors
Combination Therapy: NK cell + mAb/ICE
Pre-clinical
oNKord®
Inaleucel
Metastatic solid tumors
Combination Therapy: NK cell + mAb/ICE
PRE
TBA

viveNK™

GTA103
OGD2+ Solid Tumors
CAR-NK
Pre-clinical
viveNK™
GTA103
OGD2+ Solid Tumors
CAR-NK
PRE
TBA
GTA103
N/A
CAR-NK
Development
viveNK™
GTA103
N/A
CAR-NK
DEV
TBA
GTA201
N/D
TCR-NK
Development
viveNK™
GTA201
N/D
TCR-NK
DEV
TBA